Overview

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib